Adma Biologics (ADMA) Shares Outstanding (Weighted Average) (2011 - 2025)

Adma Biologics has reported Shares Outstanding (Weighted Average) for 15 years, with the latest figure at $238.3 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 2.24% year-over-year to $238.3 million; the trailing twelve-month figure through Dec 2025 stood at $238.3 million (up 2.24% YoY), and the FY2025 full-year result was $238.3 million, up 2.24% from the prior year.
• Shares Outstanding (Weighted Average) for Q4 2025 stood at $238.3 million, roughly flat from $238.4 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $238.4 million in Q3 2025, with the low at $32.8 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $188.0 million across 5 years, with a median of $223.0 million in 2023.
• Annual changes were most pronounced in 2021 — Shares Outstanding (Weighted Average) jumped 2982.46% — and 2022, when it plunged 71.63%.
• Adma Biologics' Shares Outstanding (Weighted Average) stood at $139.6 million in 2021, then jumped by 41.77% to $197.9 million in 2022, then increased by 13.19% to $224.0 million in 2023, then grew by 4.07% to $233.1 million in 2024, then increased by 2.24% to $238.3 million in 2025.
• The last three Shares Outstanding (Weighted Average) figures came in at $238.3 million (Q4 2025), $238.4 million (Q3 2025), and $238.3 million (Q2 2025), per Business Quant data.